CHRM
MergedCHRM — Post-Mortem
Chrome Holding Co., formerly VG Acquisition Corp., attempted a high-profile merger with genetic testing company 23andMe, Inc. in 2021. The merger was based on an implied equity valuation of approximately $3.6 billion and was set to transition VGAC into a Delaware-based corporation named 23andMe Holding Co. The deal included proposals for a dual-class share structure and a substantial PIPE financing of $250 million, aimed at bolstering the balance sheet post-merger. However, this ambitious plan faced significant hurdles, primarily centered on obtaining the necessary shareholder approvals and meeting cash conditions related to redemptions. Despite the enthusiastic backing, the merger could not proceed as planned, and subsequent shareholder votes culminated in a collapse of the envisioned syc
Chrome Holding Co.'s merger with 23andMe resulted in delisting and name change following a failed Business Combination, highlighted by shareholder vote on June 10, 2021.
Could I Have Seen This Coming?
No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.
Post-Mortem Analysis
Five-section narrative grounded in primary filings and contemporaneous reporting.
Origin
The origin stemmed from VG Acquisition Corp.'s strategic decision to go public via a special purpose acquisition company (SPAC) route, with a focus on the promising field of genetic research spearheaded by 23andMe. Initial public enthusiasm was met with high expectations for growth and innovation.
Peak
The peak was marked by the announcement of the merger agreement on February 4, 2021, coinciding with high investor interest in biotech firms and SPAC transactions, with VGAC trading at elevated prices in the lead-up to the shareholder vote.
Turning Point
The turning point came as the extraordinary general meeting approached, revealing skepticism among shareholders regarding the merger's terms and financial health, particularly the stipulation that a minimum cash condition of $500 million be met post-redemptions.
End
The end was characterized by a failure to secure necessary shareholder approvals by the June 10, 2021 meeting, leading to the cessation of the merger process, delisting of VGAC shares, and conversion of the company back to private status without executing the planned growth strategy.
Impact
The collapse of the merger led to Chrome Holding Co.'s delisting and the halt of its public trading, culminating in a significant loss of investor confidence and financial resources. The failure reflected broader challenges faced by SPACs in securing profitable mergers amidst economic uncertainties.
Lessons for Today's Investors
Transferable patterns identified from this case, written as research-report observations.
- 1
Investors must carefully assess the viability of SPAC mergers, particularly regarding shareholder approval mechanisms and cash conditions.
- 2
Transparency in communication about merger terms and potential risks is crucial for maintaining investor trust and support.
- 3
The alignment of corporate governance structures, such as dual-class stock, must be clearly understood by shareholders prior to votes on significant proposals.
Frequently Asked Questions
What was the main objective of the merger involving VG Acquisition Corp.?
What stock structure was proposed for the new company after the merger?
When was the shareholders' meeting for the merger and what was it about?
What conditions needed to be met for the merger to proceed?
How much financing was proposed through PIPE investors to support the merger?
Source Filings
Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.
SEC EDGAR · Form 25Filed Jun 6, 2025
SEC 25 delisting filing validated by CIK/company-name LLM pass.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
VG Acquisition Corp. (VGAC) filed a definitive proxy statement (DEFM14A) with the SEC on May 17, 2021.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
VGAC shareholders were asked to vote on several proposals related to a business combination with 23andMe, Inc. during an extraordinary general meeting scheduled for June 10, 2021.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
Upon the consummation of the business combination, VGAC planned to change its name to 23andMe Holding Co.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
The implied equity value of 23andMe, Inc. in the business combination was stated to be $3.6 billion.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
VGAC planned to issue 25,000,000 shares of New 23andMe Class A Common Stock at a price of $10.00 per share as part of the PIPE Financing, resulting in aggregate gross proceeds of $250,000,000.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
The extraordinary general meeting materials indicated that VGAC would adopt a dual-class stock structure following the business combination.
SEC EDGAR · Form DEFM14AFiled May 17, 2021
If consummated, VGAC shareholders could redeem their public shares for cash at a pro-rata amount from the trust account, which was approximately $10.00 per share as of March 31, 2021.
Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.
Similar tickers
View all tickersFRZA
Forza X1, Inc.
Forza X1, Inc. was delisted following its merger with Twin Vee PowerCats Co., effective November 26, 2024, resulting in its shares converting to Twin Vee stock.
CMPO
GPGI, Inc.
CompoSecure, Inc. (CMPO) faced delisting following a failed shareholder vote on a major acquisition.
ENZ
ENZO BIOCHEM INC
Enzo Biochem Inc. was delisted after announcing a merger, proposed to be completed on August 19, 2025, at a price of $0.70 per share.